New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical care MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read

MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options

MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31,

MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both

Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservation MENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc.

MENLO PARK, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the

Presentation at the American Society for Microbiology NGS Conference highlights utility of PacBio’s highly accurate long-read sequencing platform in disease surveillance MENLO PARK, Calif., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc.

Edinburgh Genomics, Oxford Genomics Centre, and University of Liverpool Centre for Genomic Research have added new PacBio Sequel II & IIe Systems to their service laboratories MENLO PARK, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc.

MENLO PARK, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific Biosciences” or the “Company”) today announced that it has priced its previously announced underwritten public offering of an aggregate of 7,400,460 shares of its common stock at a

MENLO PARK, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $85.0 million of shares of its common stock and a selling stockholder intends to offer 1,304,348 of common stock shares in an underwritten